PE20060400A1 - Formulacion farmaceutica de una sal de enantiomero de mirtazapina que no sublima - Google Patents
Formulacion farmaceutica de una sal de enantiomero de mirtazapina que no sublimaInfo
- Publication number
- PE20060400A1 PE20060400A1 PE2005000439A PE2005000439A PE20060400A1 PE 20060400 A1 PE20060400 A1 PE 20060400A1 PE 2005000439 A PE2005000439 A PE 2005000439A PE 2005000439 A PE2005000439 A PE 2005000439A PE 20060400 A1 PE20060400 A1 PE 20060400A1
- Authority
- PE
- Peru
- Prior art keywords
- mirtazapine
- pharmaceutical formulation
- sublimating
- acid
- salt
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- -1 MIRTAZAPINE ENANTIOMER SALT Chemical class 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 4
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 abstract 2
- 229960001785 mirtazapine Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- 239000011976 maleic acid Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04101664 | 2004-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060400A1 true PE20060400A1 (es) | 2006-05-27 |
Family
ID=34928990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000439A PE20060400A1 (es) | 2004-04-21 | 2005-04-20 | Formulacion farmaceutica de una sal de enantiomero de mirtazapina que no sublima |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20070111993A1 (enExample) |
| EP (1) | EP1729777B1 (enExample) |
| JP (2) | JP5260959B2 (enExample) |
| CN (2) | CN1942191B (enExample) |
| AR (1) | AR049028A1 (enExample) |
| AT (1) | ATE424210T1 (enExample) |
| AU (1) | AU2005235383B2 (enExample) |
| BR (1) | BRPI0509953A (enExample) |
| CA (1) | CA2561281C (enExample) |
| CY (1) | CY1109018T1 (enExample) |
| DE (1) | DE602005013066D1 (enExample) |
| DK (1) | DK1729777T3 (enExample) |
| EC (1) | ECSP066938A (enExample) |
| ES (1) | ES2321961T3 (enExample) |
| HR (1) | HRP20090190T1 (enExample) |
| IL (1) | IL178201A (enExample) |
| LV (1) | LV13556B (enExample) |
| MX (1) | MXPA06011830A (enExample) |
| MY (1) | MY144899A (enExample) |
| NO (1) | NO20065077L (enExample) |
| NZ (1) | NZ550052A (enExample) |
| PE (1) | PE20060400A1 (enExample) |
| PL (1) | PL1729777T3 (enExample) |
| PT (1) | PT1729777E (enExample) |
| RS (1) | RS50764B (enExample) |
| RU (1) | RU2375362C2 (enExample) |
| SI (1) | SI1729777T1 (enExample) |
| TW (1) | TW200538100A (enExample) |
| UA (1) | UA89773C2 (enExample) |
| WO (1) | WO2005102352A1 (enExample) |
| ZA (1) | ZA200608305B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA83666C2 (ru) * | 2003-07-10 | 2008-08-11 | Н.В. Органон | Способ получения энантиомерно чистого миртазапина |
| EP1792618A1 (en) * | 2005-11-30 | 2007-06-06 | Rainer Freynhagen | R-mirtazapine for the treatment of pain |
| TW200808804A (en) * | 2006-05-22 | 2008-02-16 | Organon Nv | Mirtazapine for the treatment of neuropathic pain |
| CN104095824B (zh) * | 2013-04-09 | 2016-08-31 | 上海信谊万象药业股份有限公司 | 一种米氮平缓释片及其制备方法 |
| JP6876003B2 (ja) | 2015-02-27 | 2021-05-26 | デクラ リミテッド | イヌ及びネコにおける、食欲の刺激、体重減少の管理、及び拒食症の処置 |
| CN111053735A (zh) * | 2020-02-25 | 2020-04-24 | 上海阶平医院管理有限公司 | 一种治疗失眠的冷敷凝胶 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL189199C (nl) * | 1975-04-05 | 1993-02-01 | Akzo Nv | Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten. |
| US4193828A (en) * | 1976-07-27 | 1980-03-18 | Fiber Materials, Inc. | Method of forming carbon composites |
| US4515792A (en) * | 1982-09-30 | 1985-05-07 | Ciba-Geigy Corporation | Tetracyclic heterocycles and antidepressant compositions thereof |
| IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| EP0813873B1 (en) * | 1996-06-19 | 2002-02-13 | Akzo Nobel N.V. | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| ES2212550T3 (es) * | 1998-04-02 | 2004-07-16 | Akzo Nobel N.V. | Solucion oral liquida que comprende el antidepresor mirtazapina. |
| WO2001000196A2 (en) * | 1999-06-25 | 2001-01-04 | University Of South Florida | Mirtazapine for weight gain in wasting diseases |
| US6281207B1 (en) * | 1999-09-15 | 2001-08-28 | Reed Richter | Treatment of movement disorders by administration of mirtazapine |
| WO2001042239A1 (en) * | 1999-12-13 | 2001-06-14 | Sumika Fine Chemicals Co., Ltd. | Process for the preparation of a pyridinemethanol compound |
| HK1047547B (en) * | 2000-04-05 | 2003-10-10 | Akzo Nobel N.V. | Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug |
-
2005
- 2005-04-12 TW TW094111559A patent/TW200538100A/zh unknown
- 2005-04-19 BR BRPI0509953-6A patent/BRPI0509953A/pt not_active IP Right Cessation
- 2005-04-19 RS RSP-2009/0164A patent/RS50764B/sr unknown
- 2005-04-19 WO PCT/EP2005/051714 patent/WO2005102352A1/en not_active Ceased
- 2005-04-19 UA UAA200610312A patent/UA89773C2/ru unknown
- 2005-04-19 EP EP05740221A patent/EP1729777B1/en not_active Expired - Lifetime
- 2005-04-19 CN CN2005800116628A patent/CN1942191B/zh not_active Expired - Fee Related
- 2005-04-19 DE DE602005013066T patent/DE602005013066D1/de not_active Expired - Lifetime
- 2005-04-19 PT PT05740221T patent/PT1729777E/pt unknown
- 2005-04-19 NZ NZ550052A patent/NZ550052A/en unknown
- 2005-04-19 CA CA2561281A patent/CA2561281C/en not_active Expired - Fee Related
- 2005-04-19 HR HR20090190T patent/HRP20090190T1/xx unknown
- 2005-04-19 PL PL05740221T patent/PL1729777T3/pl unknown
- 2005-04-19 RU RU2006140988/04A patent/RU2375362C2/ru not_active IP Right Cessation
- 2005-04-19 ES ES05740221T patent/ES2321961T3/es not_active Expired - Lifetime
- 2005-04-19 US US11/547,152 patent/US20070111993A1/en not_active Abandoned
- 2005-04-19 MX MXPA06011830A patent/MXPA06011830A/es not_active IP Right Cessation
- 2005-04-19 SI SI200530673T patent/SI1729777T1/sl unknown
- 2005-04-19 AT AT05740221T patent/ATE424210T1/de active
- 2005-04-19 MY MYPI20051731A patent/MY144899A/en unknown
- 2005-04-19 CN CN201010174000A patent/CN101824035A/zh active Pending
- 2005-04-19 JP JP2007508904A patent/JP5260959B2/ja not_active Expired - Fee Related
- 2005-04-19 AU AU2005235383A patent/AU2005235383B2/en not_active Expired
- 2005-04-19 DK DK05740221T patent/DK1729777T3/da active
- 2005-04-20 AR ARP050101549A patent/AR049028A1/es unknown
- 2005-04-20 PE PE2005000439A patent/PE20060400A1/es not_active Application Discontinuation
-
2006
- 2006-09-20 IL IL178201A patent/IL178201A/en not_active IP Right Cessation
- 2006-10-05 ZA ZA200608305A patent/ZA200608305B/xx unknown
- 2006-10-19 EC EC2006006938A patent/ECSP066938A/es unknown
- 2006-11-03 NO NO20065077A patent/NO20065077L/no not_active Application Discontinuation
- 2006-11-21 LV LVP-06-130A patent/LV13556B/lv unknown
-
2009
- 2009-05-05 CY CY20091100481T patent/CY1109018T1/el unknown
-
2013
- 2013-03-08 JP JP2013046645A patent/JP2013136626A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011002194A1 (es) | Formulacion que comprende anticuerpo en un regulador de histidina-arginina ph 4.5 a 6.5; articulo de manufactura que comprende dicha formulacion; metodo para estabilizar un anticuerpo en una formulacion farmaceutica acuosa. | |
| EA201001402A1 (ru) | Фармацевтические растворы, способ получения и терапевтическое применение | |
| EA201491675A1 (ru) | Новые вещества | |
| HN2004000490A (es) | Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente | |
| CL2017003445A1 (es) | Formas solidas y formulaciones de compuestos de imidazopirazina. | |
| CR11648A (es) | Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas | |
| UA115131C2 (uk) | Сполуки боронатного ефіру і його фармацевтичні рецептури | |
| EA200800168A1 (ru) | Гидрохлориды и гидраты 1-[(3-цианопиридин-2-ил)метил]-3-метил-7-(2-бутин-1-ил)-8-(3-аминопиперидин-1-ил)ксантина, их получение и их применение в качестве лекарственных средств | |
| AR054511A1 (es) | Una composicion que comprende emtricitabina y tenofovir df granuladas en seco | |
| EP1712240A4 (en) | STABLE MEDICAL WATER BASED PREPARATION WITH ANTIBODY | |
| EA200800726A1 (ru) | Введение ингибиторов дипептидилпептидазы | |
| EA200701065A1 (ru) | Инъецируемые составы, содержащие нанодисперсный оланзапин | |
| CL2009001252A1 (es) | Preparacion alimenticia que produce una sensacion de cosquilleo o quemante que comprende acido acilamino o una sal de el usos. | |
| DOP2011000329A (es) | Preparacion de solido | |
| ECSP10010588A (es) | Formulacion de medicamento solida con liberacion retardada | |
| CL2012002948A1 (es) | Formulación acuosa estable que comprende proteina almenos 5 mg/ml de proteina cd-rap y un aminoácido cargado. | |
| BRPI0812321A2 (pt) | Sais de ácido etilenodiamina dissuccínico, composição contendo os ditos sais, uso e método de preparação destes. | |
| DOP2011000245A (es) | Derivados de tiadiazoles y oxadiazoles, su preparacion y su aplicacion en terapeutica | |
| EA200970126A1 (ru) | Способ получения прегабалина и его энантиомера | |
| ECSP10010576A (es) | Formulaciones orales e inyectables de compuestos de tetraciclina | |
| DK1641438T3 (da) | Fremgangsmåde til fremstilling af den amorfe form af et lægemiddel | |
| CL2008000746A1 (es) | Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida. | |
| EA200700637A1 (ru) | Соли донепезила, подходящие для получения фармацевтических композиций | |
| BRPI0812318A2 (pt) | Aduto de ácido 1-hidroxietilideno-1, 1-difosfônico e ácido etilenodiamina disuccínio ou um sal deste, composição, método de preparação e uso deste. | |
| CO6430508A2 (es) | Procedimiento para fabricar ácido 2-[3.5-difloruro -3`-metoxi-1,1`-bifenil-4-il)amino]nicotínico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |